Brokerages Set Niagen Bioscience, Inc. (NASDAQ:NAGE) PT at $14.28

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have received a consensus rating of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.2750.

NAGE has been the subject of a number of research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Wednesday, October 8th. Canaccord Genuity Group cut their price target on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th.

Insider Activity at Niagen Bioscience

In other Niagen Bioscience news, CFO Ozan Pamir bought 4,465 shares of Niagen Bioscience stock in a transaction that occurred on Friday, November 14th. The shares were acquired at an average price of $6.81 per share, for a total transaction of $30,406.65. Following the acquisition, the chief financial officer owned 7,372 shares of the company’s stock, valued at $50,203.32. The trade was a 153.59% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 9.39% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Miller Global Investments LLC purchased a new stake in Niagen Bioscience during the 4th quarter worth $120,000. JPMorgan Chase & Co. purchased a new stake in shares of Niagen Bioscience during the third quarter worth about $3,678,000. NewEdge Advisors LLC acquired a new position in shares of Niagen Bioscience in the third quarter worth about $205,000. Caxton Associates LLP acquired a new position in shares of Niagen Bioscience in the third quarter worth about $274,000. Finally, Dark Forest Capital Management LP purchased a new position in Niagen Bioscience in the third quarter valued at about $1,773,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Niagen Bioscience Stock Down 2.8%

Shares of Niagen Bioscience stock opened at $6.57 on Monday. Niagen Bioscience has a fifty-two week low of $5.17 and a fifty-two week high of $14.69. The business’s fifty day moving average is $6.71 and its two-hundred day moving average is $8.70. The firm has a market cap of $524.35 million, a PE ratio of 27.38 and a beta of 2.35.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Niagen Bioscience had a return on equity of 24.13% and a net margin of 16.38%.The business had revenue of $33.99 million during the quarter, compared to the consensus estimate of $31.30 million.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.